New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 31, 2018 - Shionogi announced the FDA approval of Mulpleta (lusutrombopag), for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure.
Download PDF
Return to publications
